Policy analysis reveals barriers to open access in commercially funded research, suggesting funder-neutral policies ensure equitable scientific dissemination.
Pharmaceutical companies fund much biomedical research, yet many journals restrict open access publishing options for peer-reviewed articles reporting commercially funded research. Expanded publishing options, such as funder-neutral publishing policies, will help address this inequity.
No takes yet. Share an insight, caveat, or question.
Schmidt et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: